Xu Daichao, Zou Chengyu, Yuan Junying
Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China; email:
Annu Rev Genet. 2021 Nov 23;55:235-263. doi: 10.1146/annurev-genet-071719-022748.
The receptor-interacting protein kinase 1 (RIPK1) is recognized as a master upstream regulator that controls cell survival and inflammatory signaling as well as multiple cell death pathways, including apoptosis and necroptosis. The activation of RIPK1 kinase is extensively modulated by ubiquitination and phosphorylation, which are mediated by multiple factors that also control the activation of the NF-κB pathway. We discuss current findings regarding the genetic modulation of RIPK1 that controls its activation and interaction with downstream mediators, such as caspase-8 and RIPK3, to promote apoptosis and necroptosis. We also address genetic autoinflammatory human conditions that involve abnormal activation of RIPK1. Leveraging these new genetic and mechanistic insights, we postulate how an improved understanding of RIPK1 biology may support the development of therapeutics that target RIPK1 for the treatment of human inflammatory and neurodegenerative diseases.
受体相互作用蛋白激酶1(RIPK1)被认为是一种主要的上游调节因子,可控制细胞存活、炎症信号传导以及多种细胞死亡途径,包括细胞凋亡和坏死性凋亡。RIPK1激酶的激活受到泛素化和磷酸化的广泛调节,这是由多种也控制NF-κB途径激活的因素介导的。我们讨论了关于RIPK1基因调节的当前发现,该调节控制其激活以及与下游介质(如半胱天冬酶-8和RIPK3)的相互作用,以促进细胞凋亡和坏死性凋亡。我们还探讨了涉及RIPK1异常激活的遗传性自身炎症性人类疾病。利用这些新的遗传学和机制见解,我们推测对RIPK1生物学的更好理解如何支持开发针对RIPK1的疗法,用于治疗人类炎症性和神经退行性疾病。